In Brief: Genentech IGF-1
Genentech IGF-1: Development of IGF-1 for Type 1 and Type 2 diabetes mellitus to be discontinued following Phase II trials because of the time and expense required to address concerns about the effect of the growth factor on diabetic retinopathy, the company explains. Through Phase II, no IGF-1 trials showed evidence of generalized angiogenic effects on the eyes, Genentech maintains...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth